Catherine Sibyl Diefenbach

21PUBLICATIONS
158CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical bacteriologyHaematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 27, 2026
Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.

|Feb 09, 2026
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma.

Catherine Diefenbach, Opeyemi Jegede, Victoria Wang

|Nov 28, 2025
A retrospectively registered pilot randomized controlled trial of postbiotic administration during antibiotic treatment increases microbiome diversity and enriches health-associated taxa.

Jonas Schluter, William Jogia, Fanny Matheis

|Dec 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.

Matthew S Davids, Danielle M Brander, Yesid Alvarado-Valero

|Jun 27, 2024
Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma.

Edgar Gonzalez-Kozlova, Hsin-Hui Huang, Opeyemi A Jagede

|Apr 03, 2024
KLRG1, Another Opportunity for a Breakthrough in MTCL.

Gaurav Varma, Catherine S Diefenbach

Pageof 4

Frequent Collaborators

5 joint publications

Nancy L Bartlett

3 joint publications

Izidore S Lossos

3 joint publications

Stephen D Smith

3 joint publications

Gaurav Varma